Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 7

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 7
---
 Mergers are subject to the satisfaction or waiver of a number of conditions set forth in the Merger Agreement, including approval of the Merger Agreement Proposal by the stockholders of
Enfusion. We cannot complete the Mergers unless the stockholders of Enfusion vote to approve the Merger Agreement Proposal.

This Proxy Statement/Prospectus contains or references detailed information about Enfusion, Clearwater, the Special Meeting, the Merger, the Merger Agreement and the business to be considered by the stockholders of Enfusion at the Special Meeting. Please carefully read this entire Proxy Statement/Prospectus, including the section titled “ Risk Factors” beginning on page 31 of this Proxy Statement/Prospectus for a discussion of the risks relating to the Merger. You also can obtain information about Enfusion from documents that it has filed with the Securities and Exchange Commission.

Sincerely,

Oleg Movchan

Chief Executive Officer

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued in connection with the Mergers or determined if this Proxy Statement/Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

This Proxy Statement/Prospectus is dated , 2025 and is first being mailed to stockholders of Enfusion on or
about , 2025.

ENFUSION, INC. 125 South Clark Street, Suite 750 Chicago, IL 60603 NOTICE OF SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON , 2025 This is a notice that a special meeting of stockholders of Enfusion, Inc. (“ Enfusion”) will be held on , 2025, beginning at a.m., Central time. The Special Meeting will be a completely virtual, live audio webcast meeting of stockholders and will be held for the following purposes:

| 2. | to approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not 
 sufficient votes to approve the Merger Agreement Proposal (the “Adjournment Proposal”).                         |

The accompanying Proxy Statement/Prospectus describes the proposals listed above in more detail. Please refer to the accompanying Proxy Statement/Prospectus, including the Merger Agreement and the other annexes and documents included in, or incorporated by reference into, the accompanying Proxy Statement/Prospectus for further information with respect to the business to be transacted at the Special Meeting. You are encouraged to read the entire Proxy